School of Health and Rehabilitation Sciences, The Ohio State University College of Medicine, Columbus, OH, USA.
Division of Cancer Prevention and Control, The Ohio State University College of Medicine, Columbus, OH, USA.
Support Care Cancer. 2024 Jan 18;32(2):111. doi: 10.1007/s00520-024-08321-9.
National studies reporting the prevalence of cannabis use have focused on individuals with a history of cancer without distinction by their treatment status, which can impact symptom burden. While pain is a primary motivation to use cannabis in cancer, the magnitude of its association with cannabis use remains understudied.
We examined cannabis use and pain management among 5523 respondents of the Behavioral Risk Factor Surveillance System with a cancer history. Survey-weighted prevalence proportions of respondents' cannabis use are reported, stratified on cancer treatment status. Regression models estimated odds ratios (ORs) and 95% confidence intervals (CIs) of cancer-related pain and cannabis use.
Cannabis use was slightly more prevalent in those undergoing active treatment relative to those who were not undergoing active treatment (9.3% vs. 6.2%; P=0.05). Those under active treatment were more likely to use cannabis medicinally (71.6% vs. 50.0%; P=0.03). Relative to those without cancer-related pain, persons with pain under medical control (OR 2.1, 95% CI, 1.4-3.2) or uncontrolled pain were twice as likely to use cannabis (OR 2.0, 95% CI, 1.1-3.5).
Use of cannabis among cancer patients may be related to their treatment and is positively associated with cancer-related pain. Future research should investigate the associations of cannabis use, symptom burden, and treatment regimens across the treatment spectrum to facilitate interventions.
报告大麻使用流行率的全国性研究集中于有癌症病史的个体,而没有根据其治疗状况进行区分,这可能会影响症状负担。虽然疼痛是癌症患者使用大麻的主要动机,但大麻使用与疼痛之间的关联程度仍研究不足。
我们调查了行为风险因素监测系统中 5523 名有癌症病史的受访者的大麻使用和疼痛管理情况。报告了按癌症治疗状况分层的受访者大麻使用的调查加权患病率。回归模型估计了癌症相关疼痛和大麻使用的比值比(OR)和 95%置信区间(CI)。
与未接受积极治疗的患者相比,接受积极治疗的患者大麻使用略为常见(9.3%对 6.2%;P=0.05)。接受积极治疗的患者更有可能出于医疗目的使用大麻(71.6%对 50.0%;P=0.03)。与无癌症相关疼痛的患者相比,疼痛经医学控制(OR 2.1,95%CI,1.4-3.2)或未控制疼痛的患者使用大麻的可能性是其两倍(OR 2.0,95%CI,1.1-3.5)。
癌症患者使用大麻可能与其治疗有关,并且与癌症相关疼痛呈正相关。未来的研究应调查大麻使用、症状负担和治疗方案在整个治疗范围内的关联,以促进干预措施的开展。